Soleno Therapeutics Investors Seek Compensation After Losses

robot
Abstract generation in progress

A class action lawsuit has been filed against Soleno Therapeutics, Inc. (SLNO) by Robbins LLP on behalf of investors who experienced losses due to a decline in the company’s stock price. The lawsuit alleges that Soleno Therapeutics made misleading statements regarding its business and financial performance, particularly about its lead drug candidate, causing artificial inflation of its stock. When setbacks in the drug’s development were disclosed, the stock price plummeted, resulting in significant investor losses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin